Atypical inflammatory demyelinating syndromes of the CNS

The Lancet Neurology

Volumn 15, Issue 9, 2016, Pages 967-981

  Hardy, Todd A ^a   Reddel, Stephen W ^a   Barnett, Michael H ^a,b   Palace, Jacqueline ^c   Lucchinetti, Claudia F ^d   Weinshenker, Brian G ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ATYPICAL INFLAMMATORY DEMYELINATING SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; DEMYELINATING DISEASE; DEMYELINATION; HUMAN; IMMUNOBIOLOGY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PELIZAEUS MERZBACHER DISEASE; PRIORITY JOURNAL; REVIEW; SCHILDER DISEASE; BLOOD; BRAIN; COMPLICATION; DIAGNOSTIC IMAGING; IMMUNOLOGY; PATHOLOGY;

AQP4 PROTEIN, HUMAN; AQUAPORIN 4; IMMUNOGLOBULIN G;

AQUAPORIN 4; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; DEMYELINATING DISEASES; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING;

EID: 84992184044     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30043-6     Document Type: Review

References (127)

1. 1 Filippi, M, Rocca, MA, Ciccarelli, O, et al., for the MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15 (2016), 292–303.
2. 2 Hu, W, Lucchinetti, CF, The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol 31 (2009), 439–453.
3. 3 Lennon, VA, Wingerchuk, DM, Kryzer, TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 (2004), 2106–2112.
4. 4 Lucchinetti, CF, Guo, Y, Popescu, BF, Fujihara, K, Itoyama, Y, Misu, T, The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 24 (2014), 83–97.
5. 5 Wingerchuk, DM, Banwell, B, Bennett, JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 (2015), 177–189.
6. 6 Krupp, LB, Tardieu, M, Amato, MP, et al., for the International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19 (2013), 1261–1267.
7. 7 Wood, DD, Bilbao, JM, O'Connors, P, Moscarello, MA, Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 40 (1996), 18–24.
8. 8 Beniac, DR, Wood, DD, Palaniyar, N, Ottensmeyer, FP, Moscarello, MA, Harauz, G, Marburg's variant of multiple sclerosis correlates with a less compact structure of myelin basic protein. Mol Cell Biol Res Commun 1 (1999), 48–51.
9. 9 Wingerchuk, DM, Lennon, VA, Pittock, SJ, Lucchinetti, CF, Weinshenker, BG, Revised diagnostic criteria for neuromyelitis optica. Neurology 66 (2006), 1485–1489.
10. 10 Wingerchuk, DM, Lennon, VA, Lucchinetti, CF, Pittock, SJ, Weinshenker, BG, The spectrum of neuromyelitis optica. Lancet Neurol 6 (2007), 805–815.
11. 11 Pandit, L, Asgari, N, Apiwattanakul, M, et al., for the GJCF International Clinical Consortium and Biorepository for Neuromyelitis Optica. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 21 (2015), 845–853.
12. 12 Leite, MI, Coutinho, E, Lana-Peixoto, M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 78 (2012), 1601–1607.
13. 13 Wingerchuk, DM, Weinshenker, BG, The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 18 (2012), 5–10.
14. 14 Alexopoulos, H, Kampylafka, EI, Fouka, P, et al. Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. J Neuroimmunol 289 (2015), 8–11.
15. 15 Graber, DJ, Levy, M, Kerr, D, Wade, WF, Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation, 5, 2008, 22.
16. 16 Papadopoulos, MC, Verkman, AS, Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11 (2012), 535–544.
17. 17 Sato, DK, Callegaro, D, Lana-Peixoto, MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82 (2014), 474–481.
18. 18 Höftberger, R, Sepulveda, M, Armangue, T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 21:7 (2015), 866–874.
19. 19 Kitley, J, Waters, P, Woodhall, M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71 (2014), 276–283.
20. 20 Ramanathan, S, Reddel, SW, Henderson, A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm, 1, 2014, e40.
21. 21 Rostásy, K, Mader, S, Hennes, EM, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 19 (2013), 1052–1059.
22. 22 Hacohen, Y, Absoud, M, Deiva, K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm, 2, 2015, e81.
23. 23 Ketelslegers, IA, Van Pelt, DE, Bryde, S, et al. Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler 21 (2015), 1513–1520.
24. 24 Lechner, C, Baumann, M, Hennes, EM, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry, 2015, 10.1136/jnnp-2015-311743 published online Dec 8.
25. 25 Ramanathan, S, Prelog, K, Barnes, EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 22 (2016), 470–482.
26. 26 Bernard-Valnet, R, Liblau, RS, Vukusic, S, Marignier, R, Neuromyelitis optica: a positive appraisal of seronegative cases. Eur J Neurol 22 (2015), 1511–1518.
27. 27 Titulaer, MJ, Höftberger, R, Iizuka, T, et al. Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol 75 (2014), 411–428.
28. 28 Pittock, SJ, Weinshenker, BG, Lucchinetti, CF, Wingerchuk, DM, Corboy, JR, Lennon, VA, Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63 (2006), 964–968.
29. 29 Kim, HJ, Paul, F, Lana-Peixoto, MA, et al., for the Guthy-Jackson Charitable Foundation NMO International Clinical Consortium and Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 84 (2015), 1165–1173.
30. 30 Matthews, L, Marasco, R, Jenkinson, M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80 (2013), 1330–1337.
31. 31 Barnett, Y, Sutton, IJ, Ghadiri, M, Masters, L, Zivadinov, R, Barnett, MH, Conventional and advanced imaging in neuromyelitis optica. AJNR Am J Neuroradiol 35 (2014), 1458–1466.
32. 32 Garg, N, Reddel, SW, Miller, DH, et al. The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases. J Neurol Neurosurg Psychiatry 86 (2015), 1374–1382.
33. 33 Yonezu, T, Ito, S, Mori, M, et al. “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler 20 (2014), 331–337.
34. 34 Pekcevik, Y, Mitchell, CH, Mealy, MA, et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Scler 22 (2016), 302–311.
35. 35 Hyun, JW, Kim, SH, Jeong, IH, Lee, SH, Kim, HJ, Bright spotty lesions on the spinal cord: an additional MRI indicator of neuromyelitis optica spectrum disorder?. J Neurol Neurosurg Psychiatry 86 (2015), 1280–1282.
36. 36 Collongues, N, Cabre, P, Marignier, R, et al., for the Group Members for NOMADMUS and CF-SEP. A benign form of neuromyelitis optica: does it exist?. Arch Neurol 68 (2011), 918–924.
37. 37 Lucchinetti, CF, Mandler, RN, McGavern, D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125 (2002), 1450–1461.
38. 38 Fujihara, K, Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci 306 (2011), 183–187.
39. 39 Popescu, BF, Lucchinetti, CF, Pathology of demyelinating diseases. Annu Rev Pathol 7 (2012), 185–217.
40. 40 Popescu, BF, Guo, Y, Jentoft, ME, et al. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology 84 (2015), 148–158.
41. 41 Hinson, SR, Romero, MF, Popescu, BF, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 109 (2012), 1245–1250.
42. 42 Hinson, SR, McKeon, A, Fryer, JP, Apiwattanakul, M, Lennon, VA, Pittock, SJ, Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol 66 (2009), 1164–1167.
43. 43 Roemer, SF, Parisi, JE, Lennon, VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130 (2007), 1194–1205.
44. 44 Misu, T, Fujihara, K, Kakita, A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130 (2007), 1224–1234.
45. 45 Parratt, JD, Prineas, JW, Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Scler 16 (2010), 1156–1172.
46. 46 Barnett, MH, Prineas, JW, Buckland, ME, Parratt, JD, Pollard, JD, Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 18 (2012), 108–112.
47. 47 Zamvil, SS, Slavin, AJ, Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?. Neurol Neuroimmunol Neuroinflamm, 2, 2015, e62.
48. 48 Hohlfeld, R, Dornmair, K, Meinl, E, Wekerle, H, The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol 15 (2016), 317–331.
49. 49 König, FB, Wildemann, B, Nessler, S, et al. Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol 65 (2008), 1527–1532.
50. 50 Spadaro, M, Gerdes, LA, Mayer, MC, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2 (2015), 295–301.
51. 51 Di Pauli, F, Höftberger, R, Reindl, M, et al. Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflamm, 2, 2015, e175.
52. 52 Jarius, S, Metz, I, König, FB, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Mult Scler, 2016; Feb 11, 10.1177/1352458515622986.
53. 53 Magaña, SM, Keegan, BM, Weinshenker, BG, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 68 (2011), 870–878.
54. 54 Abboud, H, Petrak, A, Mealy, M, Sasidharan, S, Siddique, L, Levy, M, Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler 22 (2016), 185–192.
55. 55 Kleiter, I, Gahlen, A, Borisow, N, et al., for the Neuromyelitis Optica Study Group. Neuromyelitis optica: evaluation of 871 attacks and 1 153 treatment courses. Ann Neurol 79 (2016), 206–216.
56. 56 Trebst, C, Jarius, S, Berthele, A, et al., Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261 (2014), 1–16.
57. 57 Gelfand, JM, Cotter, J, Klingman, J, Huang, EJ, Cree, BA, Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflamm, 1, 2014, e34.
58. 58 Mealy, MA, Wingerchuk, DM, Palace, J, Greenberg, BM, Levy, M, Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71 (2014), 324–330.
59. 59 Kim, SH, Jeong, IH, Hyun, JW, et al. Treatment Outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72 (2015), 989–995.
60. 60 Pittock, SJ, Lennon, VA, McKeon, A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12 (2013), 554–562.
61. 61 Ringelstein, M, Ayzenberg, I, Harmel, J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 72 (2015), 756–763.
62. 62 Kitley, J, Woodhall, M, Waters, P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79 (2012), 1273–1337.
63. 63 Koelman, DL, Mateen, FJ, Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome. J Neurol 262 (2015), 2013–2024.
64. 64 Dale, RC, de Sousa, C, Chong, WK, Cox, TC, Harding, B, Neville, BG, Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123 (2000), 2407–2422.
65. 65 Krupp, LB, Banwell, B, Tenembaum, S, for the International Pediatric MS Study Group. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 68:16 suppl 2 (2007), S7–12.
66. 66 Peche, SS, Alshekhlee, A, Kelly, J, Lenox, J, Mar, S, A long-term follow-up study using IPMSSG criteria in children with CNS demyelination. Pediatr Neurol 49 (2013), 329–334.
67. 67 Schwarz, S, Mohr, A, Knauth, M, Wildemann, B, Storch-Hagenlocher, B, Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 56 (2001), 1313–1318.
68. 68 Marin, SE, Callen, DJ, The magnetic resonance imaging appearance of monophasic acute disseminated encephalomyelitis: an update post application of the 2007 consensus criteria. Neuroimaging Clin N Am 23 (2013), 245–266.
69. 69 Atzori, M, Battistella, PA, Perini, P, et al. Clinical and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in pediatric patients: a single centre prospective study. Mult Scler 15 (2009), 363–370.
70. 70 Reindl, M, Di Pauli, F, Rostásy, K, Berger, T, The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9 (2013), 455–461.
71. 71 Huppke, P, Rostasy, K, Karenfort, M, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler 19 (2013), 941–946.
72. 72 Baumann, M, Sahin, K, Lechner, C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 86 (2015), 265–272.
73. 73 Waters, P, Woodhall, M, O'Connor, KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm, 2, 2015, e89.
74. 74 Pröbstel, AK, Dornmair, K, Bittner, R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 77 (2011), 580–588.
75. 75 Saadoun, S, Waters, P, Owens, GP, Bennett, JL, Vincent, A, Papadopoulos, MC, Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun, 2, 2014, 35.
76. 76 Brenton, JN, Banwell, BL, Therapeutic approach to the management of pediatric demyelinating disease: multiple sclerosis and acute disseminated encephalomyelitis. Neurotherapeutics, 2015, 10.1007/s13311-015-0396-0 published online Oct 23.
77. 77 Young, NP, Weinshenker, BG, Parisi, JE, et al. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 133 (2010), 333–348.
78. 78 Menge, T, Hemmer, B, Nessler, S, et al. Acute disseminated encephalomyelitis: an update. Arch Neurol 62 (2005), 1673–1680.
79. 79 Robinson, CA, Adiele, RC, Tham, M, Lucchinetti, CF, Popescu, BF, Early and widespread injury of astrocytes in the absence of demyelination in acute haemorrhagic leukoencephalitis. Acta Neuropathol Commun, 2, 2014, 52.
80. 80 Klein, CJ, Wijdicks, EF, Earnest, F 4th, Full recovery after acute hemorrhagic leukoencephalitis (Hurst's disease). J Neurol 247 (2000), 977–979.
81. 81 Hardy, TA, Chataway, J, Tumefactive demyelination: an approach to diagnosis and management. J Neurol Neurosurg Psychiatry 84 (2013), 1047–1053.
82. 82 Jeong, IH, Kim, SH, Hyun, JW, Joung, A, Cho, HJ, Kim, HJ, Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations. J Neurol Sci 358 (2015), 118–124.
83. 83 Seewann, A, Enzinger, C, Filippi, M, et al., for the MAGNIMS network. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: A review of reported findings. J Neurol 255 (2008), 1–10.
84. 84 Wallner-Blazek, M, Rovira, A, Fillipp, M, et al. Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol 260 (2013), 2016–2022.
85. 85 Lucchinetti, CF, Gavrilova, RH, Metz, I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131 (2008), 1759–1775.
86. 86 Kiriyama, T, Kataoka, H, Taoka, T, et al. Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm. J Neuroimaging 21 (2011), e69–e77.
87. 87 Abou Zeid, N, Pirko, I, Erickson, B, et al. Diffusion-weighted imaging characteristics of biopsy-proven demyelinating brain lesions. Neurology 78 (2012), 1655–1662.
88. 88 Kim, DS, Na, DG, Kim, KH, et al. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology 251 (2009), 467–475.
89. 89 Cianfoni, A, Niku, S, Imbesi, SG, Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 28 (2007), 272–277.
90. 90 Given, CA 2nd, Stevens, BS, Lee, C, The MRI appearance of tumefactive demyelinating lesions. AJR Am J Roentgenol 182 (2004), 195–199.
91. 91 Lu, SS, Kim, SJ, Kim, HS, et al. Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions. AJNR Am J Neuroradiol 35 (2014), 270–277.
92. 92 Bolat, S, Berding, G, Dengler, R, Stangel, M, Trebst, C, Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 287 (2009), 257–259.
93. 18F-fluorodeoxyglucose-PET. Brain Tumor Pathol 28 (2011), 229–238.
94. 94 Altintas, A, Petek, B, Isik, N, et al. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler 18 (2012), 1448–1453.
95. 95 Herrlinger, U, Schabet, M, Bitzer, M, Petersen, D, Krauseneck, P, Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 43 (1999), 219–226.
96. 96 Nagappa, M, Taly, AB, Sinha, S, et al. Tumefactive demyelination: clinical, imaging and follow-up observations in thirty-nine patients. Acta Neurol Scand 128 (2013), 39–47.
97. 97 Wattamwar, PR, Baheti, NN, Kesavadas, C, Nair, M, Radhakrishnan, A, Evolution and long term outcome in patients presenting with large demyelinating lesions as their first clinical event. J Neurol Sci 297 (2010), 29–35.
98. 98 Siri, A, Carra-Dalliere, C, Ayrignac, X, et al. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study. J Neurol 262 (2015), 1637–1645.
99. 99 Munarriz, PM, Castaño-Leon, AM, Martinez-Perez, R, Hernandez-Lain, A, Ramos, A, Lagares, A, Tumefactive multiple sclerosis requiring emergency craniotomy: case report and literature review. Neurocirugia (Astur) 24 (2013), 220–224.
100. 100 Haupts, MR, Schimrigk, SK, Brune, N, et al. Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology. J Neurol 255 (2008), 1272–1273.
101. 101 Dastgir, J, DiMario, FJ Jr, Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal. J Child Neurol 24 (2009), 431–437.
102. 102 Fan, X, Mahta, A, De Jager, PL, Kesari, S, Rituximab for tumefactive inflammatory demyelination: a case report. Clin Neurol Neurosurg 114 (2012), 1326–1328.
103. 103 Pilz, G, Harrer, A, Wipfler, P, et al. Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology 81 (2013), 1654–1658.
104. 104 Hardy, TA, Miller, DH, Baló's concentric sclerosis. Lancet Neurol 13 (2014), 740–746.
105. 105 Tabira, T, Chapter 105 Concentric sclerosis (Balo's disease). Lisak, RP, Truong, DD, Carroll, WM, Bhidayasiri, R, (eds.) International neurology a clinical approach, 2009, Blackwell, Oxford, 389–390.
106. 106 Kira, J, Astrocytopathy in Balo's disease. Mult Scler 17 (2011), 771–779.
107. 107 Chaodong, W, Zhang, KN, Wu, XM, et al. Baló's disease showing benign clinical course and co-existence with multiple sclerosis-like lesions in Chinese. Mult Scler 14 (2008), 418–424.
108. 108 Masuda, H, Mori, M, Katayama, K, Kikkawa, Y, Kuwabara, S, Anti-aquaporin-4 antibody-seronegative NMO spectrum disorder with Baló's concentric lesions. Intern Med 52 (2013), 1517–1521.
109. 109 Stadelmann, C, Ludwin, S, Tabira, T, et al. Tissue preconditioning may explain concentric lesions in Balo type of multiple sclerosis. Brain 128 (2005), 979–987.
110. 110 Chitnis, T, Hollmann, TJ, CADASIL mutation and Balo concentric sclerosis: a link between demyelination and ischemia?. Neurology 78 (2012), 221–223.
111. 111 Khonsari, RH, Calvez, V, The origins of concentric demyelination: self-organization in the human brain. PLoS One, 2, 2007, e150.
112. 112 Kreft, KL, Mellema, SJ, Hintzen, RQ, Spinal cord involvement in Balo's concentric sclerosis. J Neurol Sci 279 (2009), 114–117.
113. 113 Hardy, TA, Beadnall, HN, Sutton, IJ, et al. Baló's concentric sclerosis and tumefactive demyelination: a shared immunopathogenesis?. J Neurol Sci 348 (2015), 279–281.
114. 114 Hardy, TA, Tobin, WO, Lucchinetti, CF, Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló's concentric sclerosis. Mult Scler, 2016, 10.1177/1352458516641776 published online April 1.
115. 115 Poser, CM, Goutières, F, Carpentier, MA, Aicardi, J, Schilder's myelinoclastic diffuse sclerosis. Pediatrics 77 (1986), 107–112.
116. 116 Schilder, P, Zur Kenntnis der sogennanten diffusen Sklerose. Z Gesamte Neurol Psychiatr 10 (1912), 1–60.
117. 117 Schilder, P, Zur Frage der Encephalitis periaxialis diffusa. Z Gesamte Neurol Psychiatr 15 (1913), 359–376.
118. 118 Schilder, P, Die Encephalitis periaxialis diffusa. Arch Psychiat Nervenkr 71 (1924), 327–356.
119. 119 Poser, S, Lüer, W, Bruhn, H, Frahm, J, et al. Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 86 (1992), 579–585.
120. 120 Miyamoto, N, Kagohashi, M, Nishioka, K, et al. An autopsy case of Schilder's variant of multiple sclerosis (Schilder's disease). Eur Neurol 55 (2006), 103–107.
121. 121 Marburg, O, Die sogenannte “akute Multiple Sklerose.”. J Psychiatr Neurol 27 (1906), 211–312.
122. 122 Suzuki, M, Kawasaki, H, Masaki, K, et al. An autopsy case of the Marburg variant of multiple sclerosis (acute multiple sclerosis). Intern Med 52 (2013), 1825–1832.
123. 123 Zettl, UK, Stüve, O, Patejdl, R, Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 11 (2012), 167–173.
124. 124 Mendez, MF, Pogacar, S, Malignant monophasic multiple sclerosis or “Marburg's disease”. Neurology 38 (1988), 1153–1155.
125. 125 Jeffery, DR, Lefkowitz, DS, Crittenden, JP, Treatment of Marburg variant multiple sclerosis with mitoxantrone. J Neuroimaging 14 (2004), 58–62.
126. 126 Nozaki, K, Abou-Fayssal, N, High dose cyclophosphamide treatment in Marburg variant multiple sclerosis: a case report. J Neurol Sci 296 (2010), 121–123.
127. 127 Weinshenker, BG, Tumefactive demyelinating lesions: characteristics of individual lesions, individual patients, or a unique disease entity?. Mult Scler 21 (2015), 1746–1747.